Long-term effects of caffeine therapy for apnea of prematurity.

@article{Schmidt2007LongtermEO,
  title={Long-term effects of caffeine therapy for apnea of prematurity.},
  author={Barbara Schmidt and Robin S. Roberts and Peter Graham Davis and Lex William Doyle and Keith James Barrington and Arne Ohlsson and Alfonso J Solimano and Win Tin},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 19},
  pages={
          1893-902
        }
}
BACKGROUND Methylxanthine therapy is commonly used for apnea of prematurity but in the absence of adequate data on its efficacy and safety. It is uncertain whether methylxanthines have long-term effects on neurodevelopment and growth. METHODS We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed. The primary outcome was a composite of death, cerebral palsy, cognitive delay… 

Figures and Tables from this paper

Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.

Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminphylline cannot be undermined.

Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity

This review of the literature on neonatal methylxanthine therapies found that caffeine is associated with fewer adverse effects and a wider therapeutic window when compared with theophylline, and larger doses of caffeine citrate have been shown to improve acute neonatal outcomes when administered promptly.

Comparison between Caffeine and Theophylline Therapy for Apnea of Prematurity

Caffeine was as effective as theophylline in the short­term for reducing apnea in preterm babies and was better tolerated and was easier to administer.

Timing of caffeine therapy in very low birth weight infants.

Association of early versus late caffeine administration on neonatal outcomes in very preterm neonates

In this third large-scale observational study of the Canadian Neonatal Network, Lodha et al. retrospectively investigated the effect of early versus late initiation of caffeine therapy on neonatal short-term outcomes of very preterm infants.

Caffeine: an evidence-based success story in VLBW pharmacotherapy

Caffeine has a very favorable benefit-to-risk ratio, and has become one of the most prescribed and cost-effective pharmacotherapies in the NICU, and in particular the most recent studies that have established the safety and efficacy.

Caffeine for Apnea of Prematurity: A Neonatal Success Story

Caffeine for Apnea of Prematurity was an international, multicenter, placebo-controlled randomized trial designed to determine whether survival without neurodevelopmental disability at a corrected age of 18 months is improved if apnea of prematurity is managed without methylxanthines in infants at a high risk of apneic attacks.

Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.

Neonatal caffeine therapy was no longer associated with a significantly improved rate of survival without disability in children with very low birth weights who were assessed at 5 years.

Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.

Therapeutic neonatal caffeine administration has no long-term effects on sleep duration or sleep apnea during childhood, and ex-preterm infants, regardless of caffeine status, are at risk for obstructiveSleep apnea and periodic limb movements in later childhood.

Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity

This study suggests that doxapram is not associated with an increased risk of ND, and needs to be confirmed or refuted by a large, well-designed, placebo-controlled randomized trial.
...

References

SHOWING 1-10 OF 43 REFERENCES

Caffeine therapy for apnea of prematurity.

Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight and reduced weight gain temporarily.

Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial

The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health.

Summary Proceedings From the Apnea-of-Prematurity Group

A sample framework for the study of apnea in neonates is described and future research needs are identified and undetermined role of AOP affecting long-term neurodevelopmental outcomes is identified.

Methylxanthine treatment for apnea in preterm infants.

Methylxanthines are effective in reducing the number of apneic attacks and the use of mechanical ventilation in the two to seven days after starting treatment, and caffeine would be the preferred drug.

Severity of Neonatal Retinopathy of Prematurity Is Predictive of Neurodevelopmental Functional Outcome at Age 5.5 Years

S Severity of neonatal ROP seems to be a marker for functional disability at age 5.5 years among very low birth weight survivors who had threshold ROP, particularly if they have unfavorable visual acuity.

Controversies surrounding xanthine therapy.

Apnoea of prematurity.

Caffeine for apnea of prematurity.

  • E. Bancalari
  • Medicine, Biology
    The New England journal of medicine
  • 2006
Caffeine is one of the most commonly prescribed drugs among premature infants. It is a potent respiratory stimulant indicated primarily to reduce the incidence of episodes of apnea associated with an

Preterm outcomes research: a critical component of neonatal intensive care.

  • M. Allen
  • Medicine
    Mental retardation and developmental disabilities research reviews
  • 2002
Ongoing longterm preterm neurodevelopmental studies, analysis of changes in outcomes over time and among centers, and evaluation of the longterm safety, efficacy and effectiveness of many perinatal and neonatal management strategies and proposed neuroprotective agents are all necessary for further medical and technological advances in neonatal intensive care.